Date published: 2026-3-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

Med22 Inhibitors

Med22 inhibitors represent a class of chemical compounds designed to interfere with the activity of the Med22 protein, a crucial subunit of the Mediator complex. The Mediator complex is a large, multi-protein assembly that plays a central role in the regulation of gene transcription by serving as a bridge between DNA-bound transcription factors and the RNA polymerase II machinery. Med22 is one of the essential components within this complex, contributing to the precise control of gene expression by modulating the interaction between transcription factors and the core transcriptional machinery. The inhibition of Med22, therefore, represents a strategic point of intervention for controlling the transcriptional activity of specific genes. Compounds classified as Med22 inhibitors are typically characterized by their ability to bind to the Med22 subunit, disrupting its normal function within the Mediator complex and, consequently, altering the transcriptional landscape of the cell. The development of Med22 inhibitors has garnered significant interest in the field of chemical biology, particularly due to the complex role that the Mediator complex plays in regulating diverse cellular processes. By targeting Med22, researchers can investigate the downstream effects on gene transcription, providing insights into the functional dynamics of the Mediator complex and its influence on cellular homeostasis. The structural diversity of Med22 inhibitors is a subject of active research, with various classes of molecules being synthesized and evaluated for their specificity and binding affinity. Techniques such as X-ray crystallography, NMR spectroscopy, and computational modeling are often employed to study the interaction between these inhibitors and the Med22 protein, facilitating the design of compounds with enhanced selectivity and potency. This research not only expands the understanding of Med22's role within the Mediator complex but also offers broader insights into the regulation of gene expression and the intricate mechanisms underlying cellular function.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

A histone deacetylase inhibitor that can alter chromatin structure and thus potentially affect MED22-mediated transcription regulation.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Another histone deacetylase inhibitor, similar to Trichostatin A, affecting chromatin dynamics and potentially MED22 functions.

RGFP966

1357389-11-7sc-507300
5 mg
$115.00
(0)

A selective histone deacetylase 3 inhibitor, potentially impacting MED22 functions by altering gene expression profiles.

C646

328968-36-1sc-364452
sc-364452A
10 mg
50 mg
$265.00
$944.00
5
(1)

A selective p300/CBP histone acetyltransferase inhibitor, indirectly affecting transcription processes involving MED22.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

A BET bromodomain inhibitor, potentially influencing MED22-mediated transcription by modifying chromatin accessibility.

GSK 525762A

1260907-17-2sc-490339
sc-490339A
sc-490339B
sc-490339C
sc-490339D
5 mg
10 mg
50 mg
100 mg
1 g
$300.00
$540.00
$940.00
$1680.00
$5900.00
(0)

A BET bromodomain inhibitor, like JQ1, it could affect MED22 functions by altering transcription regulation.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$90.00
$212.00
24
(2)

A selective histone deacetylase inhibitor, potentially influencing MED22's role in transcriptional regulation.

Panobinostat

404950-80-7sc-208148
10 mg
$200.00
9
(1)

A potent pan-histone deacetylase inhibitor, which might affect MED22's transcriptional regulatory roles.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$218.00
$634.00
1
(1)

A histone deacetylase inhibitor, known for altering gene expression, potentially affecting MED22 activity.